Literature DB >> 16771623

Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome.

Emil Lesho1.   

Abstract

Most of the evidence supporting the use of corticosteroids (steroids) for immune reconstitution syndrome (IRS) comes from case reports or retrospective series and is of low quality. However, when steroids are used, they have usually been associated with clinical improvement or resolution of IRS. Except in the case of hepatitis B- or C-associated IRS, there have been no reports of worsening of the IRS or adverse outcome due to steroid use. After ruling out other conditions which can mimic IRS, clinicians should strongly consider steroids when managing IRS associated with mycobacterial or fungal pathogens when there is severe disease, or when other measures have failed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16771623     DOI: 10.1586/14787210.4.3.469

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  13 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

2.  Paradoxical central nervous system immune reconstitution syndrome in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

Authors:  Sarah M Kranick; Priscila H Goncalves; Maryalice Stetler-Stevenson; Karen Aleman; Mark N Polizzotto; Richard F Little; Robert Yarchoan; Thomas S Uldrick
Journal:  Haematologica       Date:  2014-10-10       Impact factor: 9.941

3.  Development of fatal acute liver failure in HIV-HBV coinfected patients.

Authors:  Albert M Anderson; Marina B Mosunjac; Melody P Palmore; Melissa K Osborn; Andrew J Muir
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

Review 4.  Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy.

Authors:  Martyn A French
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

5.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

6.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

Review 7.  Immune reconstitution inflammatory syndrome in HIV-infected patients.

Authors:  Naomi F Walker; James Scriven; Graeme Meintjes; Robert J Wilkinson
Journal:  HIV AIDS (Auckl)       Date:  2015-02-12

8.  Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance.

Authors:  Graeme Meintjes; Molebogeng X Rangaka; Gary Maartens; Kevin Rebe; Chelsea Morroni; Dominique J Pepper; Katalin A Wilkinson; Robert J Wilkinson
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

9.  VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

Authors:  Franco Lori; Davide De Forni; Elly Katabira; Denis Baev; Renato Maserati; Sandra A Calarota; Pedro Cahn; Marco Testori; Aza Rakhmanova; Michael R Stevens
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

Review 10.  Management of patients with the immune reconstitution inflammatory syndrome.

Authors:  Suzaan Marais; Robert J Wilkinson; Dominique J Pepper; Graeme Meintjes
Journal:  Curr HIV/AIDS Rep       Date:  2009-08       Impact factor: 5.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.